Clinical Trial Update: Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating tislelizumab in combination with chemotherapy versus chemotherapy alone for urothelial carcinoma is currently active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Urothelial Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING